Table 4.
Multivariate analysis for factors associated with steatosis (CAP ≥ 248 dB/m) that entered variables duration of HIV infection (Model A), duration of ART (Model B) and cumulative use of AZT as a backbone drug (Model C) in different models
| Model A | Model B | Model C | ||||
|---|---|---|---|---|---|---|
| Duration of HIV infection | Duration of ART | Cumulative use of AZT‐Backbone | ||||
| OR [95% CI] | p value | OR [95% CI] | p value | OR [95% CI] | p value | |
| Social and demographic characteristics | ||||||
| Male gender | 6.18 [2.93 to 13.06] | <0.001 | 6.36 [3.00 to 13.44] | <0.001 | 5.82 [2.77 to 12.21] | <0.001 |
| Age (per 10 years) | 1.01 [0.77 to 1.34] | 0.929 | 1.02 [0.77 to 1.35] | 0.920 | 1.07 [0.82 to 1.40] | 0.610 |
| White race | 1.45 [0.82 to 2.55] | 0.200 | 1.45 [0.82 to 2.55] | 0.201 | 1.47 [0.83 to 2.59] | 0.186 |
| Metabolic features | ||||||
| Central obesity | 10.35 [4.29 to 25.00] | <0.001 | 10.72 [4.43 to 25.97] | <0.001 | 10.75 [4.44 to 25.99] | <0.001 |
| Type 2 diabetes | 9.44 [3.08 to 28.96] | <0.001 | 9.30 [3.05 to 28.39] | <0.001 | 9.42 [3.07 to 28.86] | <0.001 |
| Dyslipidaemia | 2.70 [1.40 to 5.20] | 0.003 | 2.74 [1.42 to 5.30] | 0.003 | 2.60 [1.35 to 5.03] | 0.004 |
| Hypertension | 0.66 [0.34 to 1.30] | 0.229 | 0.68 [0.35 to 1.34] | 0.266 | 0.69 [0.35 to 1.35] | 0.280 |
| HIV infection and ART history | ||||||
| Duration of HIV infection (per 10 years) | 1.64 [1.05 to 2.54] | 0.029 | ||||
| Detectable HIV RNA viral load (>40 copies/mm3) | 0.58 [0.28 to 1.20] | 0.141 | 0.58 [0.28 to 1.20] | 0.141 | 0.60 [0.29 to 1.24] | 0.165 |
| Duration of ART (per 10 years) | 1.68 [1.03 to 2.72] | 0.036 | ||||
| AZT‐Backbone as the most used ART (vs. TDF) | 1.90 [1.07 to 3.38] | 0.028 | ||||
ALT, alanine aminotransferase; ART, antiretroviral therapy; AZT, zidovudine; CI, confidence interval; INSTI, integrase strand transfer inhibitors; NNRTI, non‐nucleoside reverse‐transcriptase inhibitors; OR, odds ratio; PI, protease inhibitor, TDF, tenofovir.